Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 9/20 | 0.84 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.82 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.81 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.81 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.81 |
| ▸ | LDHA | P00338 | 1/20 | 0.81 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.81 |
| ▸ | FBP1 | P09467 | 1/20 | 0.81 |
| ▸ | SRC | P12931 | 1/20 | 0.81 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.81 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.81 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.81 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.81 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.81 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30203821 | 1.00 | RNASEL (0.84) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL21068029 | 1.00 | RNASEL (0.84) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL29439944 | 1.00 | RNASEL (0.84) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL31266503 | 0.93 | P2RY1 (0.83) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL21067751 | 0.93 | P2RY1 (0.83) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL23867092 | 0.93 | P2RY1 (0.83) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL1061029 | 0.93 | P2RY1 (0.83) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL15498428 | 0.93 | P2RY1 (0.83) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL29431883 | 0.93 | P2RY1 (0.83) | RNASELADORA1DNPH1PRKAB2TRPM2 | |
| SCHEMBL42104 | 0.93 | P2RY1 (0.83) | RNASELADORA1DNPH1PRKAB2TRPM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-10-31 | — | — | US | claimed |
| US-20190160029-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-30 | — | — | US | claimed |
| WO-2017192553-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-09 | — | — | WO | claimed |
| US-8895259-B2 | Method for determination of platelet function under flow conditions | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2014-11-25 | — | — | US | claimed |
| EP-1850135-B1 | Method for determining the thrombocyte function and flow conditions | SIEMENS HEALTHCARE DIAGNOSTICS (DE) | 2010-11-03 | — | — | EP | claimed |
| US-20070254324-A1 | Method for determination of platelet function under flow conditions | DADE BEHRING MARBURG GMBH | 2007-11-01 | — | — | US | claimed |
| EP-1850135-A1 | Method for determining the thrombocyte function and flow conditions | Dade Behring Marburg GmbH (DE) | 2007-10-31 | — | — | EP | claimed |
| US-20240358663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-10-31 | — | — | US | disclosed |
| CN-113993989-A | Process for producing ergothioneine | 丹麦科技大学 | 2022-01-28 | — | — | CN | disclosed |
| US-20190160029-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-30 | — | — | US | disclosed |
| US-20180355369-A1 | Method for Increasing Plant Stress Tolerance and Seed Dormancy | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2018-12-13 | — | — | US | disclosed |
| WO-2017192553-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-09 | — | — | WO | disclosed |
| EP-2508893-B1 | Control sample and kit for platelet activity tests | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2017-04-26 | — | — | EP | disclosed |
| WO-1995010354-A1 | EPOXY DERIVATIVES OF POLYACRYLIC AMIDES | MERCK PATENT GMBH (DE) | 1995-04-20 | — | — | WO | disclosed |
| EP-0565978-A1 | Artivated carriers, their fabrication and use | MERCK PATENT GmbH (DE) | 1993-10-20 | — | — | EP | disclosed |
| US-5238715-A | Aluminum oxide and/or aluminum hydroxide layer bonded to aluminum alloy body; organophosphorous ester bonded to the oxide/hydroxide layer; polymer layer bonded to phosphorous layer | ALUMINUM COMPANY OF AMERICA (US) | 1993-08-24 | — | — | US | disclosed |
| US-5132407-A | Purified inducible nitric oxide synthase flavoprotein | CORNELL RESEARCH FOUNDATION, INC. (US) | 1992-07-21 | — | — | US | disclosed |
| US-5103550-A | Coating aluminum base with aluminum oxide or hydroxide; treating with organic phosphorus-containing compound; applying polymer | ALUMINUM COMPANY OF AMERICA (US) | 1992-04-14 | — | — | US | disclosed |
| US-4266048-A | Synthesis of analogs of 3'-phosphoadenosine 5'-phosphosulfate (PAPS) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1981-05-05 | — | — | US | disclosed |
| US-4169011-A | PHOSPHORYLATION OF ADENOSINE, SULFONATION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | VASP, MYLK, EDNRB | RNASEL 2952/4885ADORA1 68/4885DNPH1 2875/4885 |
| US-20190160029-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | VASP, MYLK, EDNRB | RNASEL 2952/4885ADORA1 68/4885DNPH1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.